Additional funding will allow the MHRA and NICE to continue developing clear, proportionate guidance for digital mental health technologies, supporting safer, more effective tools for people across the UK.
Similar Posts
Class 4 Medicines Defect Notification: Special Concept Development UK Limited, Baclofen 10mg Tablets, EL(25)A/51
Special Concept Development UK Limited has informed the MHRA that the Patient Information Leaflet (PIL) for the batches listed in this notification do not contain the correct safety information.
Patient and family experiences inform antidepressant safety information review
An Expert Working Group has completed a review into how the potential risks associated with antidepressant medicines are communicated to patients
National assessment procedure for medicines
Guidance on the MHRA’s national assessment procedure for marketing authorisation applications.
Guidance: Medical devices: legal requirements for specific medical products
Information for manufacturers on the regulations that apply to prosthetic, orthotic and ophthalmic devices.
Official Statistics: Quarterly reports on the import of unlicensed medicines
Details and statistics on the import of unlicensed medicines from March 2014 onwards.
Variations to marketing authorisations (MAs)
How the MHRA processes variations to marketing authorisations.